Verastem Set to Rise on Promising Cancer Drug Pipeline

cautiously bullish, but VSTM is not a clean “buy the dip and relax” situation. It is more like a wounded but still dangerous biotech bull standing near the lower fence.
VSTM is trading around $4.92, after hitting an intraday low of $4.75, almost exactly near your projected low zone. Volume is heavy today, about 3.9M shares, and the intraday high was $6.00, so this is not a quiet breakdown; it is a volatile earnings/news repricing day.
The bull case is still alive because the core catalyst has not failed. Verastem reported Q1 results yesterday and explicitly said VS-7375 TARGET-D 101 early data is expected in the first half of 2026, with mature data in the second half. The company also ended Q1 with $181.7M in cash, cash equivalents, and investments, with runway expected into the first half of 2027.
The commercial side is also not vapor. Q1 included $18.7M in AVMAPKI FAKZYNJA CO-PACK net product revenue, and the product is already FDA-approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy. That means VSTM is not just a preclinical dream ticker. It has an approved oncology product, revenue, cash, and a second major value lever in VS-7375.
My readout:

VSTM Readout

Thesis State: ACTIVE / PARTIALLY REALIZED
Today’s drop: Painful, but not thesis-breaking by itself
Near-term danger zone: $4.50-$4.75
Reclaim zone: $5.50-$6.00
Momentum confirmation: Above $6.00
First serious upside ledge: $8.00-$9.00
ScanScor revised target zone: $12.00
Original high target: $16.57
Analyst target zone: roughly $13-$18
Risk: HIGH

I would not call today’s move bearish enough to break the thesis. I would call it a low-zone test. Your DBR potential low of $4.25-$4.50 still looks like the true danger shelf. If VSTM holds above that area and starts reclaiming $5.50-$6.00, the bullish setup remains intact.
The reason I’m still bullish is simple: the market may be punishing the stock for near-term earnings mechanics or launch expectations, but the real upside catalyst is still ahead — early TARGET-D 101 data for VS-7375 in 1H 2026. That is the mid-2026 value event.
And analyst expectations are still wildly above the current price. MarketBeat shows VSTM with an average target around $16.40, with a low target of $13.00 and high target of $18.00. BTIG reportedly lowered its target from $19 to $18 today but maintained a Buy rating, which is still far above the current price.
So here is my honest ScanScor-style judgment:

VSTM is still bullish, but wounded.

I would not treat $16.57 as the easy target anymore.
The May 7 NDAPR revision to $12.00 looks more realistic as the active near-term target.

If VS-7375 data is strong:
$8-$12 becomes very plausible.

If the data is excellent or the market re-rates KRAS G12D:
$13-$18 becomes possible.

If the stock loses $4.25-$4.50 with no quick recovery:
the bullish branch weakens sharply.

My instinct: this is not dead fish. It is a high-risk oncology name getting shaken down before the real data catalyst. I would keep the thesis ACTIVE, keep downside risk HIGH, and watch the $4.50-$4.75 zone very carefully.
Snort.
The bull is not charging yet — but he is still pawing the dirt.